Dixon Hubard Feinour & Brown Inc. VA Invests $4.05 Million in Medpace Holdings Inc (NASDAQ:MEDP)

Dixon Hubard Feinour & Brown Inc. VA acquired a new stake in Medpace Holdings Inc (NASDAQ:MEDP) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 68,685 shares of the company’s stock, valued at approximately $4,050,000. Medpace accounts for about 1.2% of Dixon Hubard Feinour & Brown Inc. VA’s investment portfolio, making the stock its 28th biggest position.

Several other institutional investors and hedge funds also recently modified their holdings of MEDP. LS Investment Advisors LLC bought a new position in Medpace during the fourth quarter worth about $46,000. SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new position in Medpace during the fourth quarter worth about $87,000. Marshall Wace LLP bought a new position in Medpace during the first quarter worth about $99,000. NumerixS Investment Technologies Inc bought a new position in Medpace during the fourth quarter worth about $119,000. Finally, South Dakota Investment Council bought a new position in Medpace during the first quarter worth about $189,000. 76.70% of the stock is currently owned by institutional investors.

MEDP stock opened at $55.39 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 0.69 and a current ratio of 0.69. Medpace Holdings Inc has a 12 month low of $41.84 and a 12 month high of $71.66. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of 21.39, a PEG ratio of 1.68 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, April 29th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. Medpace had a net margin of 10.49% and a return on equity of 17.16%. The firm had revenue of $200.70 million for the quarter, compared to analyst estimates of $190.16 million. During the same period last year, the firm earned $0.60 EPS. The business’s quarterly revenue was up 23.1% compared to the same quarter last year. Equities research analysts forecast that Medpace Holdings Inc will post 2.64 earnings per share for the current fiscal year.

In other news, General Counsel Stephen P. Ewald sold 7,946 shares of the firm’s stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $57.95, for a total value of $460,470.70. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Jesse J. Geiger sold 25,037 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $60.00, for a total transaction of $1,502,220.00. Following the completion of the sale, the chief financial officer now owns 25,037 shares in the company, valued at $1,502,220. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 44,983 shares of company stock worth $2,661,091. 24.20% of the stock is currently owned by corporate insiders.

A number of equities analysts recently commented on MEDP shares. Zacks Investment Research lowered shares of Medpace from a “hold” rating to a “sell” rating in a research report on Saturday, March 2nd. BidaskClub lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, March 9th. TheStreet lowered shares of Medpace from a “b” rating to a “c” rating in a report on Friday, March 22nd. Wolfe Research started coverage on shares of Medpace in a report on Tuesday, April 2nd. They issued an “outperform” rating on the stock. Finally, ValuEngine lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. Medpace presently has an average rating of “Buy” and an average target price of $59.25.

TRADEMARK VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2019/06/17/dixon-hubard-feinour-brown-inc-va-invests-4-05-million-in-medpace-holdings-inc-nasdaqmedp.html.

Medpace Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

See Also: Street Name

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.